• HŪMNZ Newsletter
  • Posts
  • The HŪMNZ Element: Issue 28 - The Benefits Decision Every CEO Delegates Too Early

The HŪMNZ Element: Issue 28 - The Benefits Decision Every CEO Delegates Too Early

Nearly half of large employers plan to raise deductibles or copays next year. That is a change to the employment deal, and it is being made in Finance.

Author

Tim Dennis
August 25, 2026

💡 Editor's Note

Renewal season has a predictable rhythm. Finance brings the number, the number is worse than last year, and the conversation turns to which levers are available.

Most of those levers move cost from the company to the employee. That part rarely gets named out loud.

Who did we decide should absorb this increase, and did anyone actually decide it?

Benefits renewal looks like a finance exercise because it arrives as a spreadsheet. What it settles is closer to a term of employment. Those are not the same decision, and they should not have the same owner.

Before you sign off the renewal, find out where execution is already stuck.

Five questions, about 90 seconds, and a personalized read on your own operation immediately. No call booked at the end, no gate, nothing to sit through.

Executive Brief

Bottom line: Shifting a benefits cost increase onto employees is not a finance adjustment. It is a quiet renegotiation of the employment deal, and right now it is being made in a labor market where employees have almost no way to respond.

The numbers are not in dispute. Mercer's 2027 health benefits survey, fielded across 604 US organizations between 15 April and 8 May 2026, found that 48% of large employers plan to raise deductibles or copays for 2027. Total health benefit cost is projected to rise 6.7% in 2026, pushing the average past $18,500 per employee, with prescription drug spend climbing around 9%.

So roughly half the market is choosing the same lever at the same time. That makes it feel like consensus rather than a choice.

The part worth pausing on is the timing. Employees are absorbing a larger share of a rising cost during a period when very few of them are in a position to leave over it. The bill for that arrives later, not never.

In 30 seconds

  • 48% of large US employers plan to raise deductibles or copays in 2027, according to Mercer's 2027 health benefits survey of 604 organizations.

  • Average health benefit cost is projected to exceed $18,500 per employee in 2026 on a 6.7% increase, with prescription drug spend rising roughly 9%.

  • Before approving any increase in cost-sharing, require the figure as a share of median take-home pay by wage band rather than as a total dollar amount.

⚠️ Four signals leaders should be watching this week

1. Who is actually absorbing this year's increase?

Signal: The renewal is presented as a company cost problem, and the resolution quietly lands on households.

Evidence: Mercer's 2027 health benefits survey (604 US organizations, fielded April–May 2026) found 48% of employers with 500 or more employees plan to raise deductibles or copays for 2027. Separately, KFF reported the average annual premium for family coverage at $26,993 in 2025, with employees contributing $6,850.

Implication: Cost-sharing decisions are usually approved in dollars and experienced as a percentage of pay. Those two views of the same number diverge sharply at the bottom of the wage band.

Action: Ask for the 2027 increase expressed as a share of median take-home pay, by wage band. Approve nothing until you have seen it that way.

2. Why does this decision feel cheaper than it is?

Signal: Cost-shifting produces no visible reaction, and the absence of reaction is read as acceptance.

Evidence: The US quits rate was 2.0% in June 2026 and the Bureau of Labor Statistics described it as unchanged, with 3.2 million voluntary departures against 7.4 million open roles.

Implication: A workforce that cannot move cannot signal displeasure by leaving. Quiet is not the same as fine, and it is a poor basis for concluding the decision was well received.

Action: Ask what this decision would have cost you in a tighter market, then decide whether you would still make it.

3. What is your pharmacy line doing on its own?

Signal: Drug spend is growing faster than the portfolio around it, and the response is narrowing eligibility rather than redesigning access.

Evidence: Mercer projects prescription drug benefit costs rising roughly 9% in 2026, ahead of the 6.7% total. On GLP-1 coverage for weight loss, 6% of large employers dropped it in 2026, another 5% plan to drop it or are considering it for 2027, and 27% tightened utilization controls across the same window.

Implication: Removing coverage moves a health outcome onto the employee rather than removing the underlying need. Whether that trade is acceptable is a leadership judgment, not a plan-design detail.

Action: Decide explicitly whether your GLP-1 position is a cost decision or a health-outcome decision, and be able to say which in one sentence.

4. What did you consider instead of raising the deductible?

Signal: Cost-sharing is the first lever reached for because it is the easiest one to model.

Evidence: Mercer found 31% of large employers now offer or plan to offer non-traditional medical plans such as high-performance networks and variable copay designs, with a further 38% considering them. Mercer's own framing is that employers are using "both traditional cost-sharing tactics and strategies that guide their people to higher-value care."

Implication: There is a lever that manages cost by changing where care happens rather than who pays for it. Most employers have not pulled it yet, which means the comparison is often never run.

Action: Before approving a deductible increase, ask which steerage or network option was evaluated and why it was rejected. If the answer is that nobody modeled one, you do not yet have a decision.

Stat of the Week

48%

The share of US employers with 500 or more staff planning to raise deductibles or copays in 2027, according to Mercer's 2027 health benefits survey of 604 organizations.

Half the market pulling the same lever in the same year does not make it the right lever. It makes it the default one.

Sources: Mercer, 2027 Health Benefits Survey, fielded 15 April to 8 May 2026 across 604 US organizations. Premium and contribution figures from KFF, 2025. Quits data from the US Bureau of Labor Statistics, Job Openings and Labor Turnover Survey, June 2026.

The Core Question

Every renewal produces a number, and every number gets approved by someone. The question is whether the person approving it understands what they are actually changing.

Finance can tell you what the increase costs. It cannot tell you what the increase means to a technician earning the median wage at your busiest site.

Are we managing this cost, or just moving it?

The VALŪE lens: Moving a cost off the P&L and onto a household does not reduce it. It relocates it somewhere you have stopped measuring, and it reappears later as delayed care, absence, or a resignation you did not see coming.

The CFO should own the spend. The employment deal belongs further up.

Know a CEO heading into renewal? Send this on and we will send you the Workforce Signals Scorecard.

Until next time,

The HŪMNZ Element — Weekly Pulse

If this was useful, forward it to one person: a CEO about to approve a renewal, or whoever on your leadership team will have to explain it to the floor.